RE: RE: Possibly Bayer's potential bid... Double Gad... I didn't think I implied the following in my post...
"Gad, why would Bayer, who's looking to buy a billion dollar business from Pfsize, give a ratzarse about a diddly-squat canadian company with less than 30 cents revenue per share and no profit."
Original post:
"Possibly Bayer's potential bid...for Pfizer's Animal-Health unit has analysts and investors "revisiting" another Company's extremely under valued stock price (BNC)."
The intended thought and pretty common place thinking... is to consider other companies in a sector where a major buy-out is happening. Interest has been elevated and timely to "revisit" other over-looked and particularly undervalued companies in the same sector. Their sp may also increase from this elevated interest (including BNC's in this case).
Did I suggest Bayer should.... ? Gad, nope.
And, a second point, assuming Pfsize (from above) is Pfizer... maybe the rest of the statement should compare apples-to-apples (stick to animal heath business comparisons i.e., revenue/earnings from BNC AH division).
Even though I was disappointed in BNC's Animal Health division's 2011 revenue and expense results...the net results were:
Revenue: $27.4 million, EBITBA (before R&D): $7.4 million, Income (before taxes)*: $2.9 million *prior to corp expense allocation (see page 78 in annual report)
No reason, any large or medium corp should not look at BNC's AH division if the fit makes a lot of sense and not looking for a major acquisition and can deal with the complications of the two other divisions.
But again, not suggesting Bayer is at the moment.
Enjoy the week-end! rg